AUTHORS
Doris K. Hansen, MD, Peter Forsberg, MD2, Amandeep Godara, MD3, Aster Meche, PhD4, Jiajie Chen5, David Hughes, PharmD, BCOP, MPH6, Rickard Sandin, PhD7, Hao Ding8, Guido Nador, MD9, Yong Chen10, Ying Lu11, Yi Hu12, Yujia Zhou13, Na Hong14, Yong Chen15
AFFILIATIONS
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 Colorado Blood Cancer Institute/Sarah Cannon Cancer Network, HCA-HealthONE P/SL, Denver, Colorado, United States
3 Huntsman Cancer Institute, Salt Lake City, Utah, United States
4 Pfizer Inc, Cambridge, MA, United States
5 Ividence, Inc, Newark, Delaware, United States
6 Pfizer Inc, Cambridge, Massachusetts, United States
7 Pfizer AB, Stockholm, Sweden
8 Ividence, Inc, Newark, Delaware, United States
9 Pfizer Inc., Tadworth, United Kingdom
10 Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Ividence, Inc, Newark, Delaware, United States
12 Ividence, Inc, Newark, Delaware, United States
13 School of Medicine, Yale University, New Haven, Connecticut, United States
14 School of Medicine, Yale University, New Haven, Connecticut, United States
15 Pfizer Inc, Collegeville, Pennsylvania, United States
ABSTRACT
Background
Elranatamab, a BCMA–CD3 bispecific antibody, has emerged as a new treatment option for patients with relapsed/refractory multiple myeloma (RRMM). However, evidence remains limited regarding its use in routine US practice, including step-up dosing (SUD) care settings. Using the Epic Cosmos electronic health record (EHR) database, this study aimed to characterize real-world elranatamab treatment patterns, safety, and effectiveness in the overall population and stratified by SUD care setting.
Methods
This retrospective cohort study used de-identified EHR data from Epic Cosmos, covering more than 300 million patients across ≈2000 hospitals. Adults with RRMM who initiated elranatamab in the United States between 08/14/2023 and 09/30/2025, were followed until 06/30/2026, or death, whichever occurred first. Demographic and clinical characteristics were captured during the baseline period prior to elranatamab initiation. SUD care setting, elranatamab utilization, safety, and effectiveness were evaluated during the follow-up period. Outcomes included incidence proportions of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections; time to treatment discontinuation (TTD), time to next treatment or death (TTNT/D), and real-world overall survival (rwOS). SUD setting was classified as inpatient or outpatient if the first two doses were given in the same setting, and mixed if they were given in different settings. Analyses were descriptive overall and across SUD care settings. Kaplan–Meier (KM) methods were used for rwOS and TTNT/D. Landmark rwOS was also estimated. For TTD, cumulative incidence functions (CIFs) were estimated, treating death as a competing event. Cell counts <11 were suppressed.
Results
A total of 483 patients with RRMM treated with elranatamab were identified, of whom 413 (85.6%), 45 (9.3%) and 25 (5.2%) underwent SUD in the inpatient, outpatient, and mixed settings, respectively. Among patients who received outpatient SUD, 2% initiated treatment in 2023, 38% in 2024, and 60% in 2025. The median age was 72 years, 50.3% were male, 59.4% were White, and 28.0% were Black. More than half of patients (59.0%) had a Charlson Comorbidity Index score ≥5, and 40.0% had renal disease. The median time from initial MM diagnosis to elranatamab initiation was 54.3 months (interquartile range [IQR], 25.3–94.6), and the median follow-up duration was 13.5 months (IQR, 8.6–20.1 and min-max, 0.1-31.8). Overall, 77.2% of patients received the first full 76-mg dose. Stratified by SUD care setting, 74.6% of inpatients and 88.9% of outpatients received the first full dose. CRS and ICANS were reported in 31.3% and 7.7% of patients, respectively, with 85.4% and 70.2% of events occurring during SUD. The median onset of CRS and ICANS occurred on the same calendar day as elranatamab initiation (IQR, 0–0 and 0–16, respectively). Among patients in the SUD-stratified groups, CRS was reported in 29.8% of patients in the inpatient SUD group and 24.4% of those in the outpatient SUD group. ICANS was reported in 6.1% of patients in the inpatient SUD group and not reportable in the outpatient and mixed SUD groups. Infections were observed in 41.0% of patients overall, including 40.0% in the inpatient SUD group and 35.6% in the outpatient SUD group. The median time to first infection was 56 days (IQR, 20–156) overall, 56 days (IQR, 26–164) in the inpatient SUD group, and 55 days (IQR, 24–110) in the outpatient SUD group. Median rwOS was not reached; rwOS rates were 74.2% (95% CI, 70.3–78.3) at 12 months, 69.8% (95% CI, 65.6–74.3) at 18 months, and 66.1% (95% CI, 61.1–71.6) at 24 months. Median TTNT/D was 16.1 months (95% CI, 11.1–28.1). The cumulative incidence of treatment discontinuation was 41.2% (95% CI, 36.8–45.6) at 6 months, 50.4% (95% CI, 45.8–54.9) at 12 months, and 56.0% (95% CI, 51.0–61.0) at 24 months.
Conclusions
In this elderly and heavily comorbid real-world population, median rwOS was not reached. Additional studies are warranted to better understand the influence of prophylactic treatment on infection risk. SUD was primarily delivered in the inpatient setting. Over time, outpatient SUD was increasingly adopted and showed numerically comparable safety outcomes, although comparisons were descriptive and may reflect patient selection. These findings provide evidence on elranatamab use in routine US practice and support further evaluation of outpatient SUD strategies.
DISCLOSURES
Doris K. Hansen, MD: BMS - Research Funding; BMS, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech - Research Funding; Johnson & Johnson - Research Funding; Janssen - Research Funding; Adaptive - Research Funding; Kite - Research Funding; Karyopharm - Research Funding; Kite - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); BMS, Janssen, Legend Biotech, Pfizer, Kite Pharma/Gilead Sciences, AstraZeneca, and Karyopharm - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Legend biotech - Consultancy (Includes expert testimony)